CLDX logo

CLDX
Celldex Therapeutics Inc.

9,730
Mkt Cap
$2.09B
Volume
1.88M
52W High
$34.52
52W Low
$14.40
PE Ratio
-8.05
CLDX Fundamentals
Price
$31.35
Prev Close
$31.37
Open
$30.96
50D MA
$27.75
Beta
1.14
Avg. Volume
1.02M
EPS (Annual)
-$3.90
P/B
3.96
Rev/Employee
$7,803.03
$1,292.18
Loading...
Loading...
News
all
press releases
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's Why
Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Here's Why...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?
Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above 200-Day Moving Average - Time to Sell...
MarketBeat·8d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High Following Analyst Upgrade...
MarketBeat·15d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research
Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective on the stock in a research report on Monday...
MarketBeat·15d ago
News Placeholder
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seve...
MarketBeat·16d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 3.7% - Here's Why
Celldex Therapeutics (NASDAQ:CLDX) Shares Up 3.7% - Time to Buy...
MarketBeat·18d ago
News Placeholder
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Eventide Asset Management LLC raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.1% in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·24d ago
News Placeholder
Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP
Commodore Capital LP trimmed its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 12.2% during the 3rd quarter, according to the company in its most recent Form 13F filing...
MarketBeat·24d ago
News Placeholder
Braidwell LP Makes New Investment in Celldex Therapeutics, Inc. $CLDX
Braidwell LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange...
MarketBeat·24d ago
News Placeholder
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus...
MarketBeat·25d ago
<
1
2
...
>

Latest CLDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.